AIM
AVDL

Acrospire Investment Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Acrospire Investment Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,435
Closed -$49K – 124
2017
Q2 		$49K Buy
+4,435
New +$44.5K 0.05% 871
2016
Q4 		– Sell
-2,955
Closed -$37K – 2194
2016
Q3 		$37K Buy
+2,955
New +$38.6K 0.02% 1230
2016
Q2 		– Sell
-3,955
Closed -$44K – 2014
2016
Q1 		$44K Buy
+3,955
New +$39.3K 0.03% 1054

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Acrospire Investment Management's AVDL Position: Q3 2017 in Review

Acrospire Investment Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2017, closing a stake of 4,435 shares — an estimated $49K sold.

Acrospire Investment Management first reported a position in AVDL in Q1 2016 and held it in 3 quarters. The position peaked at $49K in Q2 2017. 82 funds tracked by Wall St. Rank hold AVDL as of Q3 2017.

  • Acrospire Investment Management reported no remaining Avadel Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 4,435 Avadel Pharmaceuticals shares in Q3 2017, an estimated $49K.
  • Acrospire Investment Management first reported a position in Avadel Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Avadel Pharmaceuticals position peaked at $49K in Q2 2017.
  • 82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.